Xenetic Biosciences provided a status update on its pending all-stock acquisition of Santersus AG, which is expected to transform the company into a clinical-stage entity focused on targeting neutrophil extracellular traps (NETs). The combined company will feature a pipeline with four first-in-class programs, including pivotal-stage programs in sepsis and SLE that have received FDA Breakthrough Device Designation.
Counterparty
Santersus AG
“This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer
“We believe the complementary nature of NucleoCapture® and Xenetic's DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer
Xenetic Biosciences reported a net loss of $3.1 million for the nine months ended September 30, 2026, compared to $2.1 million in the prior year period, driven primarily by a significant increase in general and administrative expenses. Total revenue, derived from royalties, remained relatively flat at $2.2 million for the nine-month period. The company ended the quarter with $5.8 million in cash and is focused on advancing its systemic DNase program into clinical trials.
Xenetic Biosciences released an updated investor presentation regarding its pending share exchange transaction to acquire Santersus AG. The deal, originally announced on September 16, 2026, involves a proposed acquisition that will result in a combined company focused on advancing NET-targeted therapies for immune-driven diseases and cancer.
Xenetic Biosciences entered into a definitive share exchange agreement to acquire Santersus AG in an all-stock transaction. Upon closing, Santersus shareholders are expected to own approximately 85% of the combined company, which will focus on NET-targeting therapeutics and trade under the new ticker symbol SNTS.